EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with this Annual Report of Scopus BioPharma Inc. (the “Company”), on Form 10-K for the fiscal year ended December 31, 2021, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Robert J. Gibson, Principal Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) Such Annual Report on Form 10-K for the fiscal year ended December 31, 2021 fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in such Annual Report on Form 10-K for the fiscal year ended December 31, 2021 fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 15, 2022	By:	/s/ Robert J. Gibson
		Robert J. Gibson
		Vice Chairman, Secretary, and Treasurer
		(Principal Financial Officer)